With a major focus to the Chinese market, SciClone (NASDAQ:SCLN) is a specialty pharmaceutical company with a substantial business and a product portfolio of novel therapies for cancer, infectious diseases and cardiovascular, urology and central nervous system disorders, and respiratory conditions. SciClones proprietary lead product, ZADAXIN® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. Through its promotion business with pharmaceutical partners, SciClone markets multiple branded products in China which are therapeutically differentiated. The Company has successfully in-licensed products with the potential to become future market leaders and to drive the Companys long-term growth. SciClone markets nearly 20 products in China besides ZADAXIN, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China, Tritace, an ACE inhibitor for the treatment of hypertension, Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US), and Aggrastat®, a recently-launched intervention cardiology product. InJune 2017 it was announced that the firm had been acquired by GL Capital
